Humacyte (HUMA) Gross Profit (2025 - 2026)
Humacyte's (HUMA) quarterly Gross Profit came in at -$825000.0 in Q2 2026, down 1037.5% year-over-year from $88000.0 in Q2 2025, and up 46.53% quarter-over-quarter from -$1.5 million in Q1 2026.
Powered by 
Analysis
Humacyte (HUMA) Gross Profit (2025 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Gross Profit for 2 consecutive years, with -$825000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Gross Profit fell 1037.5% year-over-year to -$825000.0 in Q2 2026; TTM through Jun 2026 was -$10.5 million, a 2390.39% decrease from a year earlier, with the FY2025 full-year figure at -$7.7 million, changed N/A from the prior year.
- Gross Profit was -$825000.0 for Q2 2026 at Humacyte, up from -$1.5 million in the prior quarter.
- Over five years, Gross Profit peaked at $493000.0 in Q3 2025 and troughed at -$8.6 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.36 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.03 Bn | 5.03 Bn | - |
| 3 | Iovance Biotherapeutics | 3.64 Bn | 3.35 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn |
| 5 | uniQure | 2.98 Bn | 2.98 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.52 Bn | 2.52 Bn | - |
| 7 | Precigen | 2.38 Bn | 2.38 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.14 Bn | 1.35 Bn | 251.87 Mn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn |
| 10 | Humacyte | 134.35 Mn | 134.35 Mn | -825,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -825,000.00 |
| Mar 31, 2026 | -1.54 Mn |
| Dec 31, 2025 | -8.62 Mn |
| Sep 30, 2025 | 493,000.00 |
| Jun 30, 2025 | 88,000.00 |
| Mar 31, 2025 | 370,000.00 |